Skip to main content
Springer Nature Link
Log in

Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC)

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this retrospective study (from January 2007 to December 2011) was to investigate the efficacy and tolerability of mDCF schedule for chemotherapy-naïve AGC patients.

Patients

Patients (n = 54) with locally inoperable or distant metastasis and performance status of 0–2 were eligible. The triplet combination chemotherapy consisting of docetaxel 60 mg/m2 on day 1, cisplatin 60 mg/m2 on day 1, and 5-fluorouracil 600 mg/m2 for 5 days of continuous infusion were administered every 21 days, up to nine cycles. Prophylactic G-CSF was not allowed.

Results

In all, 36 (67 %) patients were male and 18 (33 %) were female; median age was 59 years. The majority of patients (n = 46, 85 %) had metastatic disease and 8 (15 %) of them had locally advanced disease. Liver metastasis and peritonitis carcinomatosa were found in 20 (43 %) and 18 (39 %) of the 46 cases, respectively. The median cycle of chemotherapy was 6. In assessing 50 patients for response evaluation, one had complete response. Partial response was achieved in 27 (54 %) patients. Seventeen patients (34 %) had stable disease and 5 (10 %) had progressive disease, while 4 % (n = 2) and 11 % (n = 6) of the patients developed severe (grade 3–4) neutropenia and anemia, respectively. During the median follow-up time (6.9 months, range 0.4–24), 28 (52 %) patients died. The overall and progression-free survival were 10.7 [95 % CI 8.9–12.4] and 6.8 [95 % CI 5.8–7.8] months, respectively.

Conclusions

Although this was not a prospective comparative study, the mDCF regimen seems to be as effective as the original DCF in AGC with acceptable and manageable side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Van Cutsem E, Dicato M, Geva R et al (2011) The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 22(Suppl 5):v1–v9

    Article  PubMed  Google Scholar 

  2. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150

    Article  PubMed  Google Scholar 

  3. Patel SH, Kooby DA (2011) Gastric adenocarcinoma surgery and adjuvant therapy. Surg Clin North Am 91:1039–1077

    Article  PubMed  Google Scholar 

  4. Ajani JA (2007) Recent developments in cytotoxic therapy for advanced gastric or gastroesophageal carcinoma: the phase III trials. Gastrointest Cancer Res 1:S16–S21

    PubMed  Google Scholar 

  5. Bohanes P, Courvoisier DS, Perneger TV et al (2011) Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer. Swiss Med Wkly 141:w13249

    PubMed  Google Scholar 

  6. Allum WH, Blazeby JM, Griffin SM et al (2011) Guidelines for the management of oesophageal and gastric cancer. Gut 60:1449–1472

    Article  PubMed  CAS  Google Scholar 

  7. Glimelius B, Ekstrom K, Hoffman K et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163–168

    Article  PubMed  CAS  Google Scholar 

  8. Pyrhonen S, Kuitunen T, Nyandoto P et al (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591

    Article  PubMed  CAS  Google Scholar 

  9. Nishiyama M, Wada S (2009) Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer 12:132–141

    Article  PubMed  CAS  Google Scholar 

  10. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997

    Article  PubMed  Google Scholar 

  11. Kang YK, Kang WK, Shin DB et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666–673

    Article  PubMed  Google Scholar 

  12. Roth AD, Fazio N, Stupp R et al (2007) Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 25:3217–3223

    Article  PubMed  CAS  Google Scholar 

  13. Tomasello G, Chiesa MD, Buti S et al (2010) Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel–cisplatin–5-fluorouracil regimen. Tumori 96:48–53

    PubMed  CAS  Google Scholar 

  14. Shah AM, Shibata S, Stoller RG et al (2010) Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). J Clin Oncol 28(Suppl):15s (abstr 4014)

    Google Scholar 

  15. Wang B, Zhang W, Hong X et al (2009) Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer. Cancer Chemother Pharmacol 63:213–218

    Article  PubMed  CAS  Google Scholar 

  16. Piacentini P, Durante E, Trolese A et al (2012) Weekly Taxotere and cisplatin with continuous-infusion 5-fluoruracil for the treatment of advanced gastric and esophageal cancer: a prospective, observational, single-institution experience. Gastric Cancer 15:106–110

    Article  PubMed  CAS  Google Scholar 

  17. Overman MJ, Kazmi SM, Jhamb J et al (2010) Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 116:1446–1453

    Article  PubMed  CAS  Google Scholar 

  18. Kos FT, Uncu D, Ozdemir N et al (2011) Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer. Chemotherapy 57:230–235

    Article  PubMed  CAS  Google Scholar 

  19. Inal A, Kaplan MA, Kucukoner M et al (2012) Docetaxel and cisplatin plus fluorouracil compared with modified docetaxel, cisplatin, and 5-fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. Neoplasma 59:233–236

    Article  PubMed  CAS  Google Scholar 

  20. Ajani JA, Fodor MB, Tjulandin SA et al (2005) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660–5667

    Article  PubMed  CAS  Google Scholar 

  21. Ben Aharon I, Purim O, Kundel Y et al (2012) The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: a single-institution experience. Anticancer Drugs 23:313–320

    Article  PubMed  CAS  Google Scholar 

  22. Park SR, Chun JH, Kim YW et al (2005) Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Am J Clin Oncol 28:433–438

    Article  PubMed  CAS  Google Scholar 

  23. Oh DY, Kim TY, Kwon JH et al (2005) Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. Jpn J Clin Oncol 35:380–385

    Article  PubMed  Google Scholar 

  24. Tebbutt NC, Cummins MM, Sourjina T et al (2010) Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 102:475–481

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that there are no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, 34093, Istanbul, Turkey

    S. Keskin, I. Yıldız, F. Sen, F. Aydogan, L. Kilic, M. Ekenel, B. Sakar & F. Aykan

  2. Department of Medical Oncology, Istanbul Bilim University, Istanbul, Turkey

    S. Saglam

  3. Department of Public Health, Faculty of Medicine, University of Istanbul, Istanbul, Turkey

    R. Disci

Authors
  1. S. Keskin
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. I. Yıldız
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. F. Sen
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. F. Aydogan
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. L. Kilic
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. M. Ekenel
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. S. Saglam
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. B. Sakar
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. R. Disci
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. F. Aykan
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to S. Keskin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keskin, S., Yıldız, I., Sen, F. et al. Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC). Clin Transl Oncol 15, 403–408 (2013). https://doi.org/10.1007/s12094-012-0942-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-012-0942-8

Keywords

Profiles

  1. F. Aykan View author profile